In biopharma, the most dangerous stretch of road is neither the initial hypothesis nor the final launch. It is the treacherous, capital-intensive space between early discovery and full-scale commercialization where hundreds of promising therapeutics go to die.
While conventional wisdom points to clinical trial failures and unpredicted toxicity as the primary cause of death, you might be surprised to know that the underlying root cause is often organizational and strategic—what Dr. David H. Crean defines in Dual Fluency as the Translation Gap. In short, it is a failure of leadership to communicate fluidly across the distinct languages of molecular biology, institutional capital, and corporate governance. When scientists speak only in p-values and target binding, and investors speak only in internal rates of return (IRR) and liquidation preferences, crucial strategic details fall through the cracks and can disrupt scientific leadership, productivity, and innovation.
To successfully navigate this divide, life sciences companies must master three fundamental translations:
- Data to Capital: Investors do not underwrite scientific passion; they price risk and return. Translating data into capital means taking raw preclinical assays, biomarker readouts, and patient stratification models and structuring them into clear, probability-weighted valuation trees. It is the ability to show an investor exactly how $15 million in Series A funding directly derisks the biological and regulatory profile enough to command a higher Series B valuation.
- Discovery to Deal: Securing strategic partnerships, pharma licensing agreements, or non-dilutive royalty deals requires more than presenting a pitch deck. It demands crafting deal terms, milestone triggers, and governance rights that anticipate clinical realities. A poorly structured deal can lock up a company’s core asset in regulatory limbo or trigger fatal dilution during a pipeline pivot.
- Bench to Boardroom: The operational mindset required to discover a drug is fundamentally different from the governance mindset required to steward a enterprise. Translating bench science to the boardroom requires shifting from “What else can this molecule do?” to “Where should we deploy our finite capital for maximum risk-adjusted impact?” It means developing the discipline to kill projects early, reallocate resources, and make hard fiduciary choices.
Closing the Translation Gap requires leaders with “Dual Fluency”—the rare ability to hold a rigorous, technical discussion with a head of R&D in the morning and negotiate a complex term sheet with a crossover fund in the afternoon. When science, capital, and governance move in lockstep, breakthroughs don’t just stay in the lab—they reach the patients who need them. So, read this book and gain the knowledge to learn the art of Dual Fluency and become successful in the world of science.